Open Accessibility Menu

Coronavirus (COVID-19) Vaccine Update Click here to learn more.

For information about COVID-19 or to view additional resources, please click here.

Washington DC Deep Brain Stimulation

Treatment for Intractable Pain, Movement Disorders & Mood Disorders

Deep brain stimulation (DBS) uses an electrical device much like a heart pacemaker that is implanted within the deep structures of the brain. DBS has been most commonly used to treat intractable pain, but it also can be used in movement disorders such as Parkinson's disease and dystonia. More recently, DBS has been used in the treatment of mood disorders such as obsessive compulsive disorder (OCD), and depression that does not respond to other treatments. The implanted device sends out low-level electrical signals which are thought to interrupt nerve communications that underlie these disorders.

The device is implanted in deep areas of the brain that are associated with the transmission of very basic sensations; these areas are sometimes described as way stations and are some of the first brain structures that receive nerve signals from the spinal cord. The implant itself is an electrode that delivers continuous electrical impulses to the brain area. The electrode is attached to a wire that runs under the skin and is connected ultimately to a power supply (internal pulse generator; IPG), which is placed underneath the skin near the collarbone, chest, or abdomen. DBS is associated with risks that include brain hemorrhage and infection, and is not guaranteed to provide relief.

Conveniently Located

Clinical Trials

  • This is a randomized, active-controlled, multicenter, open-label, parallel groups, Phase 2 study of DSP-7888 Dosing Emulsion plus Bevacizumab versus Bevacizumab alone in patients with recurrent or progressive glioblastoma multiforme (GBM) following treatment with first line therapy consisting of surgery and radiation with or without chemotherapy. One of the primary outcome measures is to assess the effect of DSP-7888 Dosing Emulsion plus Bevacizumab versus Bevacizumab alone on the Overall Survival of patients with recurrent or progressive GBM following treatment with first line therapy consisting of surgery and radiation with or without chemotherapy.Overall survival is defined as the interval between randomization and death from any cause
  • This is a multi-center, double-blind, randomized, parallel group, dose-ranging study to investigate the efficacy and clinical usability of STAP-001 in adult (18 years of age and older) subjects with epilepsy with a predictable seizure pattern. These subjects have an established diagnosis of focal or generalized epilepsy with a documented history of predictable seizure episodes. This is an in-patient study. The subjects will be admitted to a Clinical Research Unit (CRU) or Epilepsy Monitoring Unit (EMU) for study participation. The duration of the stay in the in-patient unit will be 2-8 days. One seizure event per subject will be treated with study medication. The duration and timing of the seizure event and occurrence of subsequent seizures will be assessed by the Staff Caregiver(s)1 through clinical observation and confirmed with video electroencephalogram (EEG).
  • A Multicenter Study of 5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor in Patients with Newly Diagnosed or Recurrent Malignant Gliomas: A Safety, Histopathology, and Correlative Biomarker Study This single arm trial is being conducted to establish the safety and efficacy of Gliolan-Æ (5-ALA) in patients undergoing resection of newly diagnosed or recurrent malignant gliomas. The rationale for the study is that Gliolan-Æ (5-ALA), as an adjunct to tumor resection, is safe and will provide surgeons with real-time visualization of malignant tumor.